Metric Analysis: Sangamo Therapeutics Inc (SGMO)’s Key Ratios in the Limelight

For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

In the latest session, Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.32 up 0.16% from its previous closing price of $0.32. In other words, the price has increased by $0.16 from its previous closing price. On the day, 3.25 million shares were traded. SGMO stock price reached its highest trading level at $0.3432 during the session, while it also had its lowest trading level at $0.3041.


For a deeper understanding of Sangamo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.71 and its Current Ratio is at 1.71. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.54.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on November 03, 2023, Downgraded its rating to Sector Perform and sets its target price to $2 from $6 previously.

On April 28, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $5 to $1.50.

Wedbush Upgraded its Neutral to Outperform on February 27, 2023, while the target price for the stock was maintained at $16.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 ’23 when BIOGEN INC. sold 6,000,000 shares for $0.50 per share. The transaction valued at 3,000,000 led to the insider holds 17,652,466 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 66921972 and an Enterprise Value of 43322000. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.57 while its Price-to-Book (P/B) ratio in mrq is 1.16. Its current Enterprise Value per Revenue stands at 2.31 whereas that against EBITDA is -0.204.

Stock Price History:

The Beta on a monthly basis for SGMO is 1.23, which has changed by -0.7714286 over the last 52 weeks, in comparison to a change of 0.26253593 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $1.67, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is -38.49%, while the 200-Day Moving Average is calculated to be -44.19%.

Shares Statistics:

For the past three months, SGMO has traded an average of 2.18M shares per day and 4136840 over the past ten days. A total of 207.51M shares are outstanding, with a floating share count of 186.71M. Insiders hold about 10.03% of the company’s shares, while institutions hold 49.05% stake in the company. Shares short for SGMO as of 1718323200 were 13798872 with a Short Ratio of 6.33, compared to 1715731200 on 14725064. Therefore, it implies a Short% of Shares Outstanding of 13798872 and a Short% of Float of 6.69.

Earnings Estimates

A comprehensive evaluation of Sangamo Therapeutics Inc (SGMO) is underway, with the input of 7.0 analysts contributing to its current rating.On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.2, while EPS last year was -$0.66. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.09 and low estimates of -$0.17.

Analysts are recommending an EPS of between -$0.23 and -$0.77 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.19, with 6.0 analysts recommending between $0.21 and -$0.62.

Revenue Estimates

A total of 5 analysts believe the company’s revenue will be $8.26M this quarter.It ranges from a high estimate of $17.8M to a low estimate of $500k. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $14.83MFor the next quarter, 5 analysts are estimating revenue of $8.72M. There is a high estimate of $13.1M for the next quarter, whereas the lowest estimate is $500k.

A total of 6 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $95M, while the lowest revenue estimate was $1.9M, resulting in an average revenue estimate of $41.15M. In the same quarter a year ago, actual revenue was $176.23MBased on 7 analysts’ estimates, the company’s revenue will be $86M in the next fiscal year. The high estimate is $232M and the low estimate is $26.4M.

Most Popular